Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California-based MediciNova has begun enrolling patients in a phase II clinical study with MN-305, a novel anti-anxiety agent licensed from Japan's Mitsubishi Pharma Corporation.
Subscribe to our email newsletter
MN-305 is described as a serotonin type 1A receptor agonist, and based on preclinical and earlier clinical studies, could hold the potential for rapid onset of anti-anxiety effect combined with excellent tolerability.
“This study signals the beginning of a very ambitious clinical development undertaking for MediciNova during 2005,” commented Dr Richard Gammans, executive vice president of clinical research at MediciNova.
“We plan to enroll 400 patients at 15 sites in the US in this study with MN-305, and before the end of this year we hope to initiate four additional phase II clinical studies with other compounds in the company’s portfolio, including potential new treatments for asthma, multiple sclerosis, interstitial cystitis, and premature labor.”
Under the licensing agreement with Mitsubishi, MediciNova obtained exclusive worldwide rights, except for Japan, China, Taiwan, South Korea and other parts of Southeast Asia, to develop and commercialize MN-305.